top of page
a VINNOVA-funded innovation initiative
a VINNOVA-funded innovation initiative
a VINNOVA-funded innovation initiative
a VINNOVA-funded innovation initiative
a VINNOVA-funded innovation initiative
TRIALS
Her2-ExPET
Title: A multicentre, prospective, open-label study with [68Ga]-Ga-ABY-025 PET imaging to characterize HER2-expression and explore the therapy predictive value for HER2-antibody drug conjugates in patients with metastatic breast cancer
EU CT number: 2024-512721-89-00
Sponsor representative: Thuy Tran - Theranostics Trial Center, Karolinska University Hospital
PI: Oscar Wiklander - Phase I, Bröstcentrum, Tema Cancer, Karolinska University Hospital/Karolinska Institutet
Status: ongoing, recruiting
Location: Stockholm, Sweden
Project summary: The overarching aim of the HER2-Ex PET trial is to study the role of precision imaging utilizing positron emission tomography (PET) with the HER2-specific tracer [68Ga]Ga-ABY-025 (hereafter referred to as HER2-PET) in enhancing treatment planning for patients with metastatic HER2-expressing breast cancer. The study hypothesis is that PET/CT precision imaging with a contemporary HER2-radiotracer ([68Ga]Ga-ABY-025) can be used for individualized treatment planning and biological understanding of HER2-expressing mBC. In this context, HER2-expressing mBC is defined as a tumor biopsy with HER2 IHC 1-3+. ABY-025 avidity on HER2-PET with a SUVmax in at least one metastatic lesion of 6 or higher is regarded as HER2-PET avid mBC.
Lut-AEA
Title: A Randomised study comparing Lutetium-177 versus Apalutamide/Enzalutamide/Abiraterone, in metastatic Hormon Sensitive Prostate Cancer in PSMA positive patients
EU CT number: 2022-500570-33-00
Sponsor representative: Region Västerbotten, Umeå University
Status: recruiting, open for inclusion
Location: Umeå, Sweden
Project summary: This randomised trial evaluates whether Lutetium-177-labelled PSMA radioligand therapy can improve outcomes with standards androgen receptor (AR)-targeted therapy (apalutamide, enzalutamide or aberiaterone) in patients with metastastic hormone-sensitive prostate cancer (mHSPC). The study focuses on patients with PSMA-positive disease as determined by molecular imaging, aiming to assess whether earlier introduction of radioligand therapy may enhance disease control in hormone-sensitive setting.
bottom of page